RCS - Oxford Cannabinoid - OCTP update from Doceo

Oxford Cannabinoid Technologies HoldingsAnnouncement

15/06/2023 10:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230615:nRSO8487Ca&default-theme=true

RNS Number : 8487C  Oxford Cannabinoid Tech.Holdings  15 June 2023

 

 

Oxford Cannabinoid Technologies Holdings plc (OCT) have launched new video
content with Doceo.

 

Oxford Cannabinoid Technologies Holdings plc, the pharmaceutical company
developing prescription cannabinoid medicines for approval by global
regulatory agencies and targeting the US$ multi-billion pain market, is
pleased to announce a new video on Doceo.

 

OCT is a dynamic biotechnology company aiming to revolutionise drug
development by utilising a diverse range of compounds, including proprietary
cannabinoid derivatives, natural phytocannabinoids, and innovative new
chemical entities (NCEs) that target the endocannabinoid system. Their
strategic approach ensures the creation of a drug development portfolio that
maximises the therapeutic potential of cannabinoids, while also driving
long-term market value and market exclusivity in all activities.

 

 

 

 

 

 

For an update on OCT, visit:
https://doceo.tv/funds/oxford-cannabinoid-technologies/
(https://doceo.tv/funds/oxford-cannabinoid-technologies/) . For further
information on Doceo please visit www.doceo.tv (https://www.doceo.tv/)  or
contact the team on info@doceo.tv (mailto:info@doceo.tv)

 

 

 

 

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFAMPTMTIBMFJ